- Home
- MED vs GNFT Comparison
MED vs GNFT Comparison
Compare MED & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- GNFT
- Stock Information
- Founded
- MED 1980
- GNFT 1999
- Country
- MED United States
- GNFT France
- Employees
- MED N/A
- GNFT N/A
- Industry
- MED Packaged Foods
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MED Consumer Staples
- GNFT Health Care
- Exchange
- MED Nasdaq
- GNFT Nasdaq
- Market Cap
- MED 187.3M
- GNFT 179.7M
- IPO Year
- MED N/A
- GNFT 2019
- Fundamental
- Price
- MED $15.48
- GNFT $3.74
- Analyst Decision
- MED Hold
- GNFT Strong Buy
- Analyst Count
- MED 1
- GNFT 1
- Target Price
- MED $17.00
- GNFT $13.00
- AVG Volume (30 Days)
- MED 204.6K
- GNFT 9.9K
- Earning Date
- MED 02-18-2025
- GNFT 09-19-2024
- Dividend Yield
- MED N/A
- GNFT N/A
- EPS Growth
- MED N/A
- GNFT N/A
- EPS
- MED 0.67
- GNFT 0.47
- Revenue
- MED $674,475,000.00
- GNFT $86,225,222.00
- Revenue This Year
- MED N/A
- GNFT $145.20
- Revenue Next Year
- MED N/A
- GNFT N/A
- P/E Ratio
- MED $23.25
- GNFT $7.89
- Revenue Growth
- MED N/A
- GNFT 175.45
- 52 Week Low
- MED $14.88
- GNFT $3.35
- 52 Week High
- MED $56.52
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- MED 36.38
- GNFT 49.41
- Support Level
- MED $15.67
- GNFT $3.68
- Resistance Level
- MED $16.30
- GNFT $4.03
- Average True Range (ATR)
- MED 0.55
- GNFT 0.15
- MACD
- MED 0.09
- GNFT 0.05
- Stochastic Oscillator
- MED 25.16
- GNFT 57.35
About MED MEDIFAST INC
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.